Quinazoline derivatives and pharmaceutical compositions...

Details Quinazoline derivatives and pharmaceutical compositions... Quinazoline derivatives and pharmaceutical compositions...

2002-02-25

2004-01-06

Ford, John M. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S266400, C514S231500, C514S228200, C544S283000, C544S284000, C544S293000, C544S106000, C544S056000, C544S059000, C544S062000

Reexamination Certificate

active

06673803

ABSTRACT:

The present invention relates to quinazoline derivatives, processes for their reparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, to their use as medicaments and to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans.
Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folknan, 1995, Nature Medicine 1: 27-31). Alteration of vascular permeability is thought to play a role in both normal and pathological physiological processes (Cullinan-Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324). Several polypeptides with in vitro endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (VEGF). By virtue of the restricted expression of its receptors, the growth factor activity of VEGF, in contrast to that of the FGFs, is relatively specific towards endothelial cells. Recent evidence indicates that VEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al, 1995, Breast Cancer Research and Treatment, 36:139-155) and vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264: 20017-20024). Antagonism of VEGF action by sequestration of VEGF with antibody can result in inhibition of tumour growth (Kim et al, 1993, Nature 362: 841-844).
Receptor tyrosine kinases (RTKs) are important in the transmission of biochemical signals across the plasma membrane of cells. These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, at least nineteen distinct RTK subfamilies, defined by amino acid sequence homology, have been identified. One of these subfamilies is presently comprised by the fms-like tyrosine kinase receptor, Flt or Flt1, the kinase insert domain-containing receptor, KDR (also referred to as Flk-1), and another fms-like tyrosine kinase receptor, Flt4. Two of these related RTKs, Flt and KDR, have been shown to bind VEGF with high affinity (De Vries et al, 1992, Science 255: 989-991; Terman et al, 1992, Biochem. Biophys. Res. Comm. 1992, 187: 1579-1586). Binding of VEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins and calcium fluxes.
European Patent Publication No. 0326330 discloses certain quinoline, quinazoline and cinnoline plant fungicides. Certain of these plant fungicides are also stated to possess insecticidal and miticidal activity. There is however no disclosure or any suggestion that any of the compounds disclosed may be used for any purpose in animals such as humans. In particular, the European Patent Publication contains no teaching whatsoever concerning angiogenesis and/or increased vascular permeability mediated by growth factors such as VEGF.
European Patent Publication No. 0566226 discloses anilinoquinazolines which have activity against epidermal growth factor (EGF) receptor tyrosine kinase. EP 0566226 contains no teaching whatsoever concerning angiogenesis and/or increased vascular permeability mediated by growth factors such as VEGF. Moreover compounds of EP 0566226 which have been tested do not show significant activity against VEGF receptor tyrosine kinase.
The present invention is based on the surprising discovery that certain quinazolines inhibit the effects of VEGF, a property of value in the treatment of disease states associated with angiogenesis and/or increased vascular permeability such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation. Compounds of the present invention possess good activity against VEGF receptor tyrosine kinase whilst possessing some activity against EGF receptor tyrosine kinase. Furthermore, some compounds of the present invention, possess substantially higher potency against VEGF receptor tyrosine kinase than against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase. Thus certain compounds of the invention which have been tested possess activity against VEGF receptor tyrosine kinase such that they may be used in an amount sufficient to inhibit VEGF receptor tyrosine kinase whilst demonstrating no significant activity against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase. While we do not wish to be bound by theoretical considerations such compounds may for example be of interest in treating tumours which are associated with VEGF, especially those tumours which are dependent on VEGF for their growth.
Other compounds of the invention possess good activity against both VEGF and EGF receptor tyrosine kinases. Indeed certain compounds possess substantially equivalent activities against VEGF and EGF receptor tyrosine kinases. It is believed that these compounds may be of interest in treating tumour states associated with both VEGF and EGF, especially where a patient is suffering from a condition in which tumours are present which are dependent on both VEGF and EGF for their growth.
According to one aspect of the present invention there is provided a quinazoline derivative of the formula I:
wherein:
m is an integer from 1 to 2;
R
1
represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C
1-3
alkyl, C
1-3
alkoxy, C
1-3
alkylthio, or —NR
5
R
6
(wherein R
5
and R
6
, which may be the same or different, each represents hydrogen or C
1-3
alkyl);
R
2
represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro:
R
3
represents hydroxy, halogeno, C
1-3
alkyl, C
1-3
alkoxy, C
1-3
alkanoyloxy, trifluoromethyl, cyano, amino or nitro;
X
1
represents —O—, —CH
2
—, —S—, —SO—, —SO
2
—, —NR
7
CO—, —CONR
8
—, —SO
2
NR
9
—, —NR
10
SO
2
— or —NR
11
− (wherein R
7
, R
8
, R
9
, R
10
and R
11
each independently represents hydrogen, C
1-3
alkyl or C
1-3
alkoxyC
2-3
alkyl);
R
4
is selected from one of the following eight groups:
1) C
1-5
alkylR
12
(wherein R
12
is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to C
1-5
alkyl through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C
1-4
alkyl, C
1-4
hydroxyalkyl and C
1-4
alkoxy, and additional possible substituents are carbamoyl, C
1-4
alkylcarbamoyl,
N
,
N
-di(C
1-4
alkyl)carbamoyl, C
1-4
alkanoyl and C
1-4
alkoxycarbonyl) or C
1-5
alkylR
13
(wherein R
13
is a group selected from pyrrolidin-1-yl, imidazolidin-1-yl and thiomorpholino, which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C
1-4
alkyl, C
1-4
hydroxyalkyl and C
1-4
alkoxy, and additional possible substituents are carbamoyl, C
1-4
alkylcarbamoyl,
N
,
N
-di(C
1-4
alkyl)carbamoyl, C
1-4
alkanoyl and C
1-4
alkoxycarbonyl);
2) C
2-5
alkenylR
14
(wherein R
14

Affiliated with

Also associated with

Rating

Quinazoline derivatives and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinazoline derivatives and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives and pharmaceutical compositions... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3238967